Theravance Biopharma Statistics
Total Valuation
TBPH has a market cap or net worth of $465.42 million. The enterprise value is $412.51 million.
| Market Cap | 465.42M |
| Enterprise Value | 412.51M |
Important Dates
The next estimated earnings date is Monday, August 5, 2024, after market close.
| Earnings Date | Aug 5, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
TBPH has 48.63 million shares outstanding. The number of shares has decreased by -23.28% in one year.
| Shares Outstanding | 48.63M |
| Shares Change (YoY) | -23.28% |
| Shares Change (QoQ) | -2.16% |
| Owned by Insiders (%) | 6.09% |
| Owned by Institutions (%) | 104.27% |
| Float | 19.34M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | 7.18 |
| PS Ratio | 7.57 |
| Forward PS | 7.76 |
| PB Ratio | 2.27 |
| P/FCF Ratio | n/a |
| PEG Ratio | -0.05 |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 6.71 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 5.74, with a Debt / Equity ratio of 0.23.
| Current Ratio | 5.74 |
| Quick Ratio | 5.33 |
| Debt / Equity | 0.23 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -14.31 |
Financial Efficiency
Return on equity (ROE) is -19.00% and return on invested capital (ROIC) is -16.75%.
| Return on Equity (ROE) | -19.00% |
| Return on Assets (ROA) | -11.10% |
| Return on Capital (ROIC) | -16.75% |
| Revenue Per Employee | $621,313 |
| Profits Per Employee | -$452,212 |
| Employee Count | 99 |
| Asset Turnover | 0.15 |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, TBPH has paid $7.58 million in taxes.
| Income Tax | 7.58M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -0.93% in the last 52 weeks. The beta is 0.24, so TBPH's price volatility has been lower than the market average.
| Beta (5Y) | 0.24 |
| 52-Week Price Change | -0.93% |
| 50-Day Moving Average | 8.92 |
| 200-Day Moving Average | 9.44 |
| Relative Strength Index (RSI) | 61.11 |
| Average Volume (20 Days) | 429,021 |
Short Selling Information
The latest short interest is 5.86 million, so 12.06% of the outstanding shares have been sold short.
| Short Interest | 5.86M |
| Short Previous Month | 6.29M |
| Short % of Shares Out | 12.06% |
| Short % of Float | 30.32% |
| Short Ratio (days to cover) | 15.91 |
Income Statement
In the last 12 months, TBPH had revenue of $61.51 million and -$44.77 million in losses. Loss per share was -$0.88.
| Revenue | 61.51M |
| Gross Profit | 61.51M |
| Operating Income | -42.33M |
| Pretax Income | -37.19M |
| Net Income | -44.77M |
| EBITDA | -28.73M |
| EBIT | -34.76M |
| Loss Per Share | -$0.88 |
Balance Sheet
The company has $100.81 million in cash and $47.90 million in debt, giving a net cash position of $52.91 million or $1.09 per share.
| Cash & Cash Equivalents | 100.81M |
| Total Debt | 47.90M |
| Net Cash | 52.91M |
| Net Cash Per Share | $1.09 |
| Equity (Book Value) | 204.87M |
| Book Value Per Share | 4.21 |
| Working Capital | 102.63M |
Cash Flow
In the last 12 months, operating cash flow was -$16.80 million and capital expenditures -$338,000, giving a free cash flow of -$17.14 million.
| Operating Cash Flow | -16.80M |
| Capital Expenditures | -338,000 |
| Free Cash Flow | -17.14M |
| FCF Per Share | -$0.36 |
Margins
Gross margin is 100.00%, with operating and profit margins of -68.82% and -72.78%.
| Gross Margin | 100.00% |
| Operating Margin | -68.82% |
| Pretax Margin | -60.46% |
| Profit Margin | -72.78% |
| EBITDA Margin | -46.71% |
| EBIT Margin | -56.51% |
| FCF Margin | -27.86% |
Dividends & Yields
TBPH does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | 23.28% |
| Shareholder Yield | 23.28% |
| Earnings Yield | -9.62% |
| FCF Yield | -3.68% |
Analyst Forecast
The average price target for TBPH is $20.50, which is 114.21% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $20.50 |
| Price Target Difference | 114.21% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 2 |
| Revenue Growth Forecast (5Y) | 30.67% |
| EPS Growth Forecast (5Y) | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
TBPH has an Altman Z-Score of -1.61 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -1.61 |
| Piotroski F-Score | 3 |